WEI LI
Physician at Clubhouse Rd, North Merrick, NY

2012009, Apr 19, 2012

Apr 1, 2010

13/262285

Pirouz M. Daftarian - Miami FL, US
Paolo Serafini - Miami Shores FL, US
Vance Paul Lemmon - Miami FL, US
Angel Kaifer - Coral Gables FL, US
Victor L. Perez - Pinecrest FL, US
Wei Li - Miami FL, US
Bonnie Beth Blomberg - Coral Gables FL, US

UNIVERSITY OF MIAMI - Miami FL

A61K 31/785, A61P 35/00, C12N 15/09, A61P 37/04, C08G 69/48, C12N 5/07

424 7817, 525 541, 435375, 435440

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle -based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE). Negatively-charged plasmids bind naturally to a positively-charged PADRE-dendrimer, while peptide or polypeptide antigens can be chemically linked to the PADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The compositions, kits, vaccines and methods described herein have both prophylactic and treatment applications, i.e., can be used as a prophylactic to prevent onset of a disease or condition in a subject, as well as to treat a subject having a disease or condition. A vaccine as described herein can be used to mount an immune response against any infectious pathogen or cancer.

2007001, Jan 11, 2007

Jun 28, 2006

11/476376

Scheffer Tseng - Pinecrest FL, US
Hua He - Miami FL, US
Wei Li - Miami FL, US

C12N 5/06, C12N 5/08

435325000, 435366000

An ex vivo method of expanding animal cells whose differentiation state is controllable by modulating TGF-β signaling includes the steps of: (a) providing an animal subject having cells with a first phenotype; (b) isolating the cells from the animal subject; (c) placing the cells in an ex vivo culture system including a culture vessel having at least one surface and a medium in contact with the at least one surface, the medium being essentially free of intact amniotic membrane and feeder cells; and (d) culturing the cells in the medium under conditions which downregulate TGF-β signaling in the cells and allow the cells to proliferate while maintaining the first phenotype.

2011020, Aug 25, 2011

Jun 9, 2009

13/062860

Wei Li - Miami Beach FL, US
Xiaoyu Jiang - Miami FL, US
Nora Blanca Caberoy - Miami FL, US

UNIVERSITY OF MIAMI - Miami FL

C40B 30/04, C40B 40/08, C12Q 1/68, C12N 15/63

506 9, 506 17, 435 612, 4353201

A dual display phage system for the identification of protein interaction networks and therapeutic targets.